$PBYI
PUMA BIOTECHNOLOGY, INC.

2023 Q4 Form 10-Q Financial Statement

#000143774923030028 Filed on November 02, 2023

View on sec.gov

Income Statement

Concept 2023 Q4 2023 Q3
Revenue $72.18M $56.12M
YoY Change 9.9% -1.73%
Cost Of Revenue $24.32M $13.28M
YoY Change 44.47% 6.31%
Gross Profit $47.86M $42.83M
YoY Change -2.01% -3.98%
Gross Profit Margin 66.3% 76.33%
Selling, General & Admin $20.18M $22.80M
YoY Change -19.39% -4.84%
% of Gross Profit 42.18% 53.23%
Research & Development $12.87M $11.45M
YoY Change -6.61% 1.72%
% of Gross Profit 26.9% 26.72%
Depreciation & Amortization $2.889M $100.0K
YoY Change 30.9% -50.0%
% of Gross Profit 6.04% 0.23%
Operating Expenses $33.06M $34.25M
YoY Change -14.85% -2.75%
Operating Profit $14.80M $8.585M
YoY Change 47.74% 258.75%
Interest Expense -$2.635M $3.339M
YoY Change -4.53% 13.3%
% of Operating Profit -17.81% 38.89%
Other Income/Expense, Net $641.0K -$2.576M
YoY Change -414.22% -4.1%
Pretax Income $12.80M $6.009M
YoY Change -341.04% -2150.85%
Income Tax $536.0K $213.0K
% Of Pretax Income 4.19% 3.54%
Net Earnings $12.27M $5.796M
YoY Change -318.84% -1710.0%
Net Earnings / Revenue 17.0% 10.33%
Basic Earnings Per Share $0.12
Diluted Earnings Per Share $0.26 $0.12
COMMON SHARES
Basic Shares Outstanding 47.57M 47.51M
Diluted Shares Outstanding 47.82M

Balance Sheet

Concept 2023 Q4 2023 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $95.94M $85.00M
YoY Change 18.34% 9.03%
Cash & Equivalents $84.59M $81.80M
Short-Term Investments $11.35M $3.200M
Other Short-Term Assets $912.0K $1.988M
YoY Change -62.45% -51.63%
Inventory $7.080M $5.679M
Prepaid Expenses $4.417M $3.684M
Receivables $47.84M $28.97M
Other Receivables $21.05M $5.700M
Total Short-Term Assets $156.2M $125.4M
YoY Change 16.31% 2.45%
LONG-TERM ASSETS
Property, Plant & Equipment $855.0K $907.0K
YoY Change -25.39% -29.25%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $4.825M $5.500M
YoY Change 3.54% 85.31%
Total Long-Term Assets $74.34M $78.25M
YoY Change -15.31% 2.4%
TOTAL ASSETS
Total Short-Term Assets $156.2M $125.4M
Total Long-Term Assets $74.34M $78.25M
Total Assets $230.5M $203.6M
YoY Change 3.81% 2.43%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $6.889M $5.061M
YoY Change 6.97% -66.09%
Accrued Expenses $52.72M $33.77M
YoY Change -0.59% -14.91%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $34.00M $22.66M
YoY Change
Total Short-Term Liabilities $99.38M $67.36M
YoY Change 28.26% 12.29%
LONG-TERM LIABILITIES
Long-Term Debt $65.66M $76.63M
YoY Change -33.21% -21.8%
Other Long-Term Liabilities $12.05M $20.90M
YoY Change -51.16% 12.16%
Total Long-Term Liabilities $65.66M $76.63M
YoY Change -33.21% -21.8%
TOTAL LIABILITIES
Total Short-Term Liabilities $99.38M $67.36M
Total Long-Term Liabilities $65.66M $76.63M
Total Liabilities $177.1M $164.9M
YoY Change -11.66% -6.65%
SHAREHOLDERS EQUITY
Retained Earnings -$1.345B -$1.357B
YoY Change -1.58% -0.27%
Common Stock $1.399B $1.396B
YoY Change 0.74% 0.93%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $53.44M $38.74M
YoY Change
Total Liabilities & Shareholders Equity $230.5M $203.6M
YoY Change 3.81% 2.43%

Cashflow Statement

Concept 2023 Q4 2023 Q3
OPERATING ACTIVITIES
Net Income $12.27M $5.796M
YoY Change -318.84% -1710.0%
Depreciation, Depletion And Amortization $2.889M $100.0K
YoY Change 30.9% -50.0%
Cash From Operating Activities $10.46M $10.61M
YoY Change 36.08% -38.52%
INVESTING ACTIVITIES
Capital Expenditures $45.00K $30.00K
YoY Change -99.36%
Acquisitions
YoY Change
Other Investing Activities -$8.125M $11.21M
YoY Change 66.74% 40.16%
Cash From Investing Activities -$8.170M $11.17M
YoY Change -31.19% 39.66%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 0.000
YoY Change -100.0% -100.0%
NET CHANGE
Cash From Operating Activities 10.46M 10.61M
Cash From Investing Activities -8.170M 11.17M
Cash From Financing Activities 0.000 0.000
Net Change In Cash 2.285M 21.78M
YoY Change -229.9% -13.59%
FREE CASH FLOW
Cash From Operating Activities $10.46M $10.61M
Capital Expenditures $45.00K $30.00K
Free Cash Flow $10.41M $10.58M
YoY Change 1424.16%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023Q3 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
514000 usd
CY2022Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
0 usd
CY2023Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2023Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2023Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
47542790
CY2023Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
47542790
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
46345660
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
46345660
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
100000 usd
us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
200000 usd
CY2022Q4 us-gaap Restricted Cash
RestrictedCash
2600000 usd
us-gaap Operating Lease Impairment Loss
OperatingLeaseImpairmentLoss
0 usd
CY2023Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
9700000 usd
CY2023Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
9700000 usd
CY2023Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
9700000 usd
CY2023Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
9700000 usd
CY2023Q3 pbyi Finitelived Intangible Asset Expected Amortization Year Six
FinitelivedIntangibleAssetExpectedAmortizationYearSix
9700000 usd
us-gaap Payments Of Debt Extinguishment Costs
PaymentsOfDebtExtinguishmentCosts
2000000 usd
CY2022Q3 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
200000 usd
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
600000 usd
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-35703
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
77-0683487
dei Entity Address Address Line1
EntityAddressAddressLine1
10880 Wilshire Boulevard, Suite 2150
dei Entity Address City Or Town
EntityAddressCityOrTown
Los Angeles
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
90024
dei City Area Code
CityAreaCode
424
dei Local Phone Number
LocalPhoneNumber
248-6500
dei Security12b Title
Security12bTitle
Common Stock, par value $0.0001 per share
dei Trading Symbol
TradingSymbol
PBYI
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
47571332
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
81800000 usd
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
76201000 usd
CY2023Q3 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
3229000 usd
CY2022Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
4873000 usd
CY2023Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
28974000 usd
CY2022Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
40350000 usd
CY2023Q3 us-gaap Inventory Net
InventoryNet
5679000 usd
CY2022Q4 us-gaap Inventory Net
InventoryNet
4526000 usd
CY2023Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
3684000 usd
CY2022Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
5902000 usd
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
222059000 usd
CY2023Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
56116000 usd
CY2023Q3 us-gaap Other Assets Current
OtherAssetsCurrent
1988000 usd
CY2022Q4 us-gaap Other Assets Current
OtherAssetsCurrent
2429000 usd
CY2023Q3 us-gaap Assets Current
AssetsCurrent
125354000 usd
CY2022Q4 us-gaap Assets Current
AssetsCurrent
134281000 usd
CY2023Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
8540000 usd
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
11362000 usd
CY2023Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
907000 usd
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1146000 usd
CY2023Q3 us-gaap Intangible Assets Net Including Goodwill
IntangibleAssetsNetIncludingGoodwill
63305000 usd
CY2022Q4 us-gaap Intangible Assets Net Including Goodwill
IntangibleAssetsNetIncludingGoodwill
70610000 usd
CY2023Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
2591000 usd
CY2022Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
2591000 usd
CY2023Q3 us-gaap Prepaid Expense And Other Assets Noncurrent
PrepaidExpenseAndOtherAssetsNoncurrent
2908000 usd
CY2022Q4 us-gaap Prepaid Expense And Other Assets Noncurrent
PrepaidExpenseAndOtherAssetsNoncurrent
2069000 usd
CY2023Q3 us-gaap Assets
Assets
203605000 usd
CY2022Q4 us-gaap Assets
Assets
222059000 usd
CY2023Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
5061000 usd
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
6440000 usd
CY2023Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
33773000 usd
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
53034000 usd
CY2023Q3 pbyi Accrued Inlicensed Rights Current
AccruedInlicensedRightsCurrent
0 usd
CY2022Q4 pbyi Accrued Inlicensed Rights Current
AccruedInlicensedRightsCurrent
12500000 usd
CY2023Q3 pbyi Post Marketing Commitment Liability Current
PostMarketingCommitmentLiabilityCurrent
1236000 usd
CY2022Q4 pbyi Post Marketing Commitment Liability Current
PostMarketingCommitmentLiabilityCurrent
1370000 usd
CY2023Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
4628000 usd
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
4140000 usd
CY2023Q3 us-gaap Long Term Debt Current
LongTermDebtCurrent
22664000 usd
CY2022Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
0 usd
CY2023Q3 us-gaap Liabilities Current
LiabilitiesCurrent
67362000 usd
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
77484000 usd
CY2023Q3 pbyi Accrued Liabilities Noncurrent
AccruedLiabilitiesNoncurrent
7739000 usd
CY2022Q4 pbyi Accrued Liabilities Noncurrent
AccruedLiabilitiesNoncurrent
7391000 usd
CY2023Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
8296000 usd
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
11834000 usd
CY2023Q3 pbyi Postmarketing Commitment Liability Noncurrent
PostmarketingCommitmentLiabilityNoncurrent
4832000 usd
CY2022Q4 pbyi Postmarketing Commitment Liability Noncurrent
PostmarketingCommitmentLiabilityNoncurrent
5435000 usd
CY2023Q3 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
76634000 usd
CY2022Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
98307000 usd
CY2023Q3 us-gaap Liabilities
Liabilities
164863000 usd
CY2022Q4 us-gaap Liabilities
Liabilities
200451000 usd
CY2023Q3 us-gaap Common Stock Value
CommonStockValue
5000 usd
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
5000 usd
CY2023Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1396173000 usd
CY2022Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1388358000 usd
CY2023Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-4000 usd
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
0 usd
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1357432000 usd
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1366755000 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
38742000 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
21608000 usd
CY2023Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
203605000 usd
CY2022Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
57102000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
163459000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
162356000 usd
CY2023Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
13284000 usd
CY2022Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
12495000 usd
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
38359000 usd
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
38257000 usd
CY2023Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
22801000 usd
CY2022Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
23961000 usd
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
69749000 usd
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
64939000 usd
CY2023Q3 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
11446000 usd
CY2022Q3 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
11253000 usd
us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
37509000 usd
us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
38456000 usd
CY2023Q3 pbyi Acquired Inprocess Research And Development
AcquiredInprocessResearchAndDevelopment
0 usd
CY2022Q3 pbyi Acquired Inprocess Research And Development
AcquiredInprocessResearchAndDevelopment
7000000 usd
pbyi Acquired Inprocess Research And Development
AcquiredInprocessResearchAndDevelopment
0 usd
pbyi Acquired Inprocess Research And Development
AcquiredInprocessResearchAndDevelopment
7000000 usd
CY2023Q3 us-gaap Costs And Expenses
CostsAndExpenses
47531000 usd
CY2022Q3 us-gaap Costs And Expenses
CostsAndExpenses
54709000 usd
us-gaap Costs And Expenses
CostsAndExpenses
145617000 usd
us-gaap Costs And Expenses
CostsAndExpenses
148652000 usd
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
8585000 usd
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
2393000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
17842000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
13704000 usd
CY2023Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
689000 usd
CY2022Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
216000 usd
us-gaap Investment Income Interest
InvestmentIncomeInterest
1886000 usd
us-gaap Investment Income Interest
InvestmentIncomeInterest
294000 usd
CY2023Q3 us-gaap Interest Expense
InterestExpense
3339000 usd
CY2022Q3 us-gaap Interest Expense
InterestExpense
2947000 usd
us-gaap Interest Expense
InterestExpense
9976000 usd
us-gaap Interest Expense
InterestExpense
8313000 usd
CY2023Q3 pbyi Legal Verdict Expense Credit
LegalVerdictExpenseCredit
0 usd
CY2022Q3 pbyi Legal Verdict Expense Credit
LegalVerdictExpenseCredit
-19000 usd
pbyi Legal Verdict Expense Credit
LegalVerdictExpenseCredit
0 usd
pbyi Legal Verdict Expense Credit
LegalVerdictExpenseCredit
-92000 usd
CY2023Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
74000 usd
CY2022Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
64000 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
118000 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
176000 usd
CY2023Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-2576000 usd
CY2022Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-2686000 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-7972000 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-7935000 usd
CY2023Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
6009000 usd
CY2022Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-293000 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
9870000 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
5769000 usd
CY2023Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
213000 usd
CY2022Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
67000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
547000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
161000 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
5796000 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-360000 usd
us-gaap Net Income Loss
NetIncomeLoss
9323000 usd
us-gaap Net Income Loss
NetIncomeLoss
5608000 usd
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.12
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.01
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.2
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.13
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.12
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.01
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.2
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.13
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
47520338
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
45567739
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
46977127
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
44290432
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
47819234
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
45567739
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
47397209
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
44464682
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
5796000 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-360000 usd
us-gaap Net Income Loss
NetIncomeLoss
9323000 usd
us-gaap Net Income Loss
NetIncomeLoss
5608000 usd
CY2023Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
2000 usd
CY2022Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
0 usd
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-4000 usd
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
2000 usd
CY2023Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
5798000 usd
CY2022Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-360000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
9319000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
5610000 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
30399000 usd
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2545000 usd
CY2023Q3 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
0 usd
CY2023Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
2000 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
5796000 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
38742000 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
19738000 usd
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2830000 usd
CY2022Q3 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
0 usd
CY2022Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
-53000 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-360000 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
22155000 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
21608000 usd
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
7815000 usd
us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
0 usd
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-4000 usd
us-gaap Net Income Loss
NetIncomeLoss
9323000 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
38742000 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
-2446000 usd
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
9198000 usd
us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
0 usd
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
9793000 usd
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
2000 usd
us-gaap Net Income Loss
NetIncomeLoss
5608000 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
22155000 usd
us-gaap Net Income Loss
NetIncomeLoss
9323000 usd
us-gaap Net Income Loss
NetIncomeLoss
5608000 usd
us-gaap Depreciation And Amortization
DepreciationAndAmortization
8630000 usd
us-gaap Depreciation And Amortization
DepreciationAndAmortization
7387000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
7815000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
9198000 usd
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
514000 usd
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
0 usd
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-0 usd
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-1000 usd
us-gaap Asset Impairment Charges
AssetImpairmentCharges
625000 usd
us-gaap Asset Impairment Charges
AssetImpairmentCharges
0 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-10862000 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-4496000 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
1153000 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-1657000 usd
us-gaap Increase Decrease In Prepaid Expenses Other
IncreaseDecreaseInPrepaidExpensesOther
-1379000 usd
us-gaap Increase Decrease In Prepaid Expenses Other
IncreaseDecreaseInPrepaidExpensesOther
-3160000 usd
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
-441000 usd
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
3663000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1379000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
3753000 usd
pbyi Increase Decrease In Operating Lease Assets And Liabilities Net
IncreaseDecreaseInOperatingLeaseAssetsAndLiabilitiesNet
853000 usd
pbyi Increase Decrease In Operating Lease Assets And Liabilities Net
IncreaseDecreaseInOperatingLeaseAssetsAndLiabilitiesNet
674000 usd
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-18913000 usd
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-53762000 usd
pbyi Increase Decrease In Postmarketing Commitment Liability
IncreaseDecreaseInPostmarketingCommitmentLiability
-737000 usd
pbyi Increase Decrease In Postmarketing Commitment Liability
IncreaseDecreaseInPostmarketingCommitmentLiability
-671000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
16554000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-23510000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
95000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
-0 usd
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
12511000 usd
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
-0 usd
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
14151000 usd
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
18977000 usd
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
12500000 usd
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
-0 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-10955000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
18977000 usd
us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
0 usd
us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
10000000 usd
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
-0 usd
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
208000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
0 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
9792000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
5599000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
5259000 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
78792000 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
75292000 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
84391000 usd
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
80551000 usd
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
0 usd
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
7000000 usd
us-gaap Interest Paid Net
InterestPaidNet
8721000 usd
us-gaap Interest Paid Net
InterestPaidNet
7412000 usd
us-gaap Income Taxes Paid
IncomeTaxesPaid
491000 usd
us-gaap Income Taxes Paid
IncomeTaxesPaid
141000 usd
pbyi Number Of Subsidiaries
NumberOfSubsidiaries
1 pure
CY2022 pbyi Number Of Subsidiaries
NumberOfSubsidiaries
2 pure
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
5800000 usd
us-gaap Net Income Loss
NetIncomeLoss
9300000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
16600000 usd
CY2023Q3 pbyi Cash Cash Equivalents And Marketable Securities
CashCashEquivalentsAndMarketableSecurities
85000000 usd
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: left; text-indent: 0pt;"><b>Use of Estimates: </b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt; text-align: left;">The preparation of consolidated financial statements in conformity with Generally Accepted Accounting Principles (“GAAP”) in the United States, requires management to make estimates and assumptions that affect reported amounts of assets and liabilities, and disclosure of contingent assets and liabilities at the date of the balance sheet, and reported amounts of revenues and expenses for the period presented. Accordingly, actual results could differ from those estimates.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt; text-align: left;">Significant estimates include estimates for variable consideration for which reserves were established. These estimates are included in the calculation of net revenues and include trade discounts and allowances, product returns, provider chargebacks and discounts, government rebates, payor rebates, and other incentives, such as voluntary patient assistance, and other allowances that are offered within contracts between the Company and its customers, payors, and other indirect customers relating to the Company’s sale of its products.</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt; text-align: left;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 0pt; text-align: left;"></p>
us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 0pt; text-align: left;"><b>Reclassification</b>:</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt; text-align: left;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: left; text-indent: 27pt;">Certain prior year amounts have been reclassified for consistency with the current year presentation. These reclassifications had <em style="font: inherit;">no</em> effect on the reported results of operations. An adjustment to the presentation of operating lease assets and liabilities, net has been made to the Condensed Consolidated Statements of Cash Flows for the <em style="font: inherit;">nine</em> months ended <em style="font: inherit;"> September 30, 2022.</em></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt; text-align: left;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: left; text-indent: 0pt;"></p>
CY2023Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
0 usd
CY2023Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
4000 usd
CY2023Q3 pbyi Cash Cash Equivalents And Shortterm Investments Fair Value
CashCashEquivalentsAndShorttermInvestmentsFairValue
48268000 usd
CY2023Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7414863
CY2022Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7925589
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7438925
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
8688594
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
5796000 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-360000 usd
us-gaap Net Income Loss
NetIncomeLoss
9323000 usd
us-gaap Net Income Loss
NetIncomeLoss
5608000 usd
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
47520338
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
45567739
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
46977127
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
44290432
CY2023Q3 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
298896
CY2022Q3 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
0
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
420082
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
174250
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
47819234
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
45567739
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
47397209
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
44464682
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.12
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.01
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.2
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.13
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.12
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.01
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.2
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.13
CY2023Q3 pbyi Sublease Agreement Potential Milestone Payments
SubleaseAgreementPotentialMilestonePayments
579800000 usd
CY2022Q4 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
46546000 usd
CY2022Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
0 usd
CY2022Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
-0 usd
CY2022Q4 pbyi Cash Cash Equivalents And Shortterm Investments Fair Value
CashCashEquivalentsAndShorttermInvestmentsFairValue
46546000 usd
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: left; text-indent: 0pt;"><b>Concentration of Risk: </b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt; text-align: left;">Financial instruments, which potentially subject the Company to concentrations of credit risk, principally consist of cash and cash equivalents, marketable securities, and accounts receivable, net. The Company’s cash and cash equivalents and restricted cash in excess of the Federal Deposit Insurance Corporation and the Securities Investor Protection Corporation insured <span style="background-color:#ffffff;">limits at </span><em style="font: inherit;"> September 30, 2023</em><span style="background-color:#ffffff;"> were approximately </span>$83.2<span style="background-color:#ffffff;"> million. The Company does <em style="font: inherit;">not</em> believe it is exposed to any significant credit risk due to the quality nature of the financial instruments in which the money is held. Pursuant to the Company’s internal investment policy, investments must be rated A-<em style="font: inherit;">1/P</em>-<em style="font: inherit;">1</em> or better by Standard and Poor’s Rating Service and Moody’s Investors Service at the time of purchase.</span></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt; text-align: left;">The Company sells its products in the United States primarily through specialty pharmacies and specialty distributors. Therefore, wholesale distributors and large pharmacy chains account for a large portion of its accounts receivables, net and product revenues, net. The creditworthiness of its customers is continuously monitored, and the Company has internal policies regarding customer credit limits. The Company estimates an allowance for doubtful accounts primarily based on the creditworthiness of its customers, historical payment patterns, aging of receivable balances and general economic conditions. </p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt; text-align: left;">The Company’s success depends on its ability to successfully commercialize NERLYNX. The Company currently has a single product and limited commercial sales experience, which makes it difficult to evaluate its current business, predict its future prospects and forecast financial performance and growth. The Company has invested a significant portion of its efforts and financial resources in the development and commercialization of the lead product, NERLYNX, and expects NERLYNX to constitute the vast majority of product revenue for the foreseeable future.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt; text-align: left;">The Company relies exclusively on <em style="font: inherit;">third</em> parties to formulate and manufacture NERLYNX and its drug candidates. The commercialization of NERLYNX and any other drug candidates, if approved, could be stopped, delayed or made less profitable if those <em style="font: inherit;">third</em> parties fail to provide sufficient quantities of product or fail to do so at acceptable quality levels or prices. The Company has <em style="font: inherit;">no</em> experience in drug formulation or manufacturing and does <em style="font: inherit;">not</em> intend to establish its own manufacturing facilities. While the drug candidates were being developed by Pfizer, both the drug substance and drug product are manufactured by <em style="font: inherit;">third</em>-party contractors. The Company is using the same <em style="font: inherit;">third</em>-party contractors to manufacture, supply, store and distribute drug supplies for clinical trials and the commercialization of NERLYNX and intends to use <em style="font: inherit;">third</em> party contractors to manufacture, supply, store and distribute drug supplies for its clinical trials of alisertib. If the Company is unable to continue its relationships with <em style="font: inherit;">one</em> or more of these <em style="font: inherit;">third</em>-party contractors, it could experience delays in the development or commercialization efforts as it locates and qualifies new manufacturers.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: left; text-indent: 0pt;"></p>
CY2023Q3 pbyi Cash And Cash Equivalents And Restricted Cash In Excess Of Insured Limits
CashAndCashEquivalentsAndRestrictedCashInExcessOfInsuredLimits
83200000 usd
CY2023Q3 us-gaap Restricted Cash
RestrictedCash
2600000 usd
CY2023Q3 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
48272000 usd
CY2023Q3 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
1269000 usd
CY2022Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
1679000 usd
CY2023Q3 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
3432000 usd
CY2022Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
2661000 usd
CY2023Q3 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
978000 usd
CY2022Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
186000 usd
CY2023Q3 us-gaap Inventory Net
InventoryNet
5679000 usd
CY2022Q4 us-gaap Inventory Net
InventoryNet
4526000 usd
CY2023Q3 pbyi Average Incremental Borrowing Rate
AverageIncrementalBorrowingRate
0.109 pure
CY2023Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
2400000 usd
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
7300000 usd
CY2022Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
2000000 usd
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
6000000 usd
CY2023Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year
FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
2400000 usd
CY2023Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
9700000 usd
CY2023Q3 pbyi Finitelived Intangible Asset Expected Amortization Year Seven
FinitelivedIntangibleAssetExpectedAmortizationYearSeven
2400000 usd
CY2022Q4 pbyi Payroll Tax Credit
PayrollTaxCredit
3800000 usd
CY2023Q1 pbyi Payroll Tax Credit
PayrollTaxCredit
3800000 usd
CY2023Q3 pbyi Prepaid Other Clinical Development Current
PrepaidOtherClinicalDevelopmentCurrent
826000 usd
CY2022Q4 pbyi Prepaid Other Clinical Development Current
PrepaidOtherClinicalDevelopmentCurrent
1408000 usd
CY2023Q3 us-gaap Prepaid Insurance
PrepaidInsurance
408000 usd
CY2022Q4 us-gaap Prepaid Insurance
PrepaidInsurance
2318000 usd
CY2023Q3 pbyi Prepaid Professional Fess Current
PrepaidProfessionalFessCurrent
1026000 usd
CY2022Q4 pbyi Prepaid Professional Fess Current
PrepaidProfessionalFessCurrent
300000 usd
CY2023Q3 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
1418000 usd
CY2022Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
1445000 usd
CY2023Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
3684000 usd
CY2023Q3 pbyi Trade Accounts Receivable Net Excluding License Revenue Receivable
TradeAccountsReceivableNetExcludingLicenseRevenueReceivable
23813000 usd
CY2022Q4 pbyi Trade Accounts Receivable Net Excluding License Revenue Receivable
TradeAccountsReceivableNetExcludingLicenseRevenueReceivable
27600000 usd
CY2023Q3 pbyi Royalty Revenue Receivable
RoyaltyRevenueReceivable
5675000 usd
CY2022Q4 pbyi Royalty Revenue Receivable
RoyaltyRevenueReceivable
12750000 usd
CY2023Q3 us-gaap Accounts Receivable Gross
AccountsReceivableGross
29488000 usd
CY2022Q4 us-gaap Accounts Receivable Gross
AccountsReceivableGross
40350000 usd
CY2023Q3 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
514000 usd
CY2022Q4 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
-0 usd
CY2023Q3 us-gaap Accounts Receivable Net
AccountsReceivableNet
28974000 usd
CY2022Q4 us-gaap Accounts Receivable Net
AccountsReceivableNet
40350000 usd
CY2023Q3 pbyi Prepaid Cro Services Current
PrepaidCROServicesCurrent
6000 usd
CY2022Q4 pbyi Prepaid Cro Services Current
PrepaidCROServicesCurrent
431000 usd
CY2022Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
5902000 usd
CY2023Q3 pbyi Prepaid Other Clinical Development Expense Noncurrent
PrepaidOtherClinicalDevelopmentExpenseNoncurrent
168000 usd
CY2022Q4 pbyi Prepaid Other Clinical Development Expense Noncurrent
PrepaidOtherClinicalDevelopmentExpenseNoncurrent
0 usd
CY2023Q3 us-gaap Prepaid Expense Other Noncurrent
PrepaidExpenseOtherNoncurrent
2740000 usd
CY2022Q4 us-gaap Prepaid Expense Other Noncurrent
PrepaidExpenseOtherNoncurrent
2069000 usd
CY2023Q3 us-gaap Prepaid Expense And Other Assets Noncurrent
PrepaidExpenseAndOtherAssetsNoncurrent
2908000 usd
CY2022Q4 us-gaap Prepaid Expense And Other Assets Noncurrent
PrepaidExpenseAndOtherAssetsNoncurrent
2069000 usd
CY2023Q3 us-gaap Prepaid Expense And Other Assets
PrepaidExpenseAndOtherAssets
6592000 usd
CY2022Q4 us-gaap Prepaid Expense And Other Assets
PrepaidExpenseAndOtherAssets
7971000 usd
CY2023Q3 us-gaap Operating Lease Expense
OperatingLeaseExpense
1200000 usd
us-gaap Operating Lease Expense
OperatingLeaseExpense
3700000 usd
CY2022Q3 us-gaap Operating Lease Expense
OperatingLeaseExpense
1200000 usd
us-gaap Operating Lease Expense
OperatingLeaseExpense
3700000 usd
us-gaap Operating Lease Payments
OperatingLeasePayments
4546000 usd
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
0 usd
CY2023Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P2Y6M
CY2023Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.109 pure
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
1419000 usd
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
5805000 usd
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
5983000 usd
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
1509000 usd
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
14716000 usd
CY2023Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
1792000 usd
CY2023Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
12924000 usd
CY2023Q3 us-gaap Sublease Income
SubleaseIncome
100000 usd
us-gaap Sublease Income
SubleaseIncome
300000 usd
CY2023Q3 us-gaap Lessor Operating Lease Payments To Be Received Remainder Of Fiscal Year
LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear
209000 usd
CY2023Q3 us-gaap Lessor Operating Lease Payments To Be Received Next Twelve Months
LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths
1013000 usd
CY2023Q3 us-gaap Lessor Operating Lease Payments To Be Received Two Years
LessorOperatingLeasePaymentsToBeReceivedTwoYears
1044000 usd
CY2023Q3 us-gaap Lessor Operating Lease Payments To Be Received Three Years
LessorOperatingLeasePaymentsToBeReceivedThreeYears
266000 usd
CY2023Q3 us-gaap Lessor Operating Lease Payments To Be Received
LessorOperatingLeasePaymentsToBeReceived
2533000 usd
CY2023Q3 us-gaap Long Term Debt Current
LongTermDebtCurrent
22664000 usd
CY2023Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
8668000 usd
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
8572000 usd
CY2023Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
7761000 usd
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
7426000 usd
CY2023Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
907000 usd
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1146000 usd
CY2023Q3 us-gaap Depreciation
Depreciation
100000 usd
us-gaap Depreciation
Depreciation
300000 usd
CY2022Q3 us-gaap Depreciation
Depreciation
200000 usd
us-gaap Depreciation
Depreciation
500000 usd
CY2023Q3 us-gaap Finite Lived License Agreements Gross
FiniteLivedLicenseAgreementsGross
102500000 usd
CY2022Q4 us-gaap Finite Lived License Agreements Gross
FiniteLivedLicenseAgreementsGross
102500000 usd
CY2023Q3 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
39195000 usd
CY2022Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
31890000 usd
CY2023Q3 us-gaap Intangible Assets Net Including Goodwill
IntangibleAssetsNetIncludingGoodwill
63305000 usd
CY2022Q4 us-gaap Intangible Assets Net Including Goodwill
IntangibleAssetsNetIncludingGoodwill
70610000 usd
CY2023Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
2400000 usd
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
7300000 usd
CY2023Q3 us-gaap Finite Lived Intangible Asset Useful Life
FiniteLivedIntangibleAssetUsefulLife
P6Y6M
CY2023Q3 pbyi Accrued Legal Verdict Expense Current
AccruedLegalVerdictExpenseCurrent
0 usd
CY2022Q4 pbyi Accrued Legal Verdict Expense Current
AccruedLegalVerdictExpenseCurrent
8000000 usd
CY2023Q3 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
9575000 usd
CY2022Q4 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
13585000 usd
CY2023Q3 pbyi Accrued Development Costs
AccruedDevelopmentCosts
893000 usd
CY2022Q4 pbyi Accrued Development Costs
AccruedDevelopmentCosts
1796000 usd
CY2023Q3 pbyi Accrued Variable Consideration Current
AccruedVariableConsiderationCurrent
9034000 usd
CY2022Q4 pbyi Accrued Variable Consideration Current
AccruedVariableConsiderationCurrent
12304000 usd
CY2023Q3 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
5161000 usd
CY2022Q4 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
7667000 usd
CY2023Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
4227000 usd
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
4301000 usd
CY2023Q3 pbyi Accrued Clinical Expenses Current
AccruedClinicalExpensesCurrent
1247000 usd
CY2022Q4 pbyi Accrued Clinical Expenses Current
AccruedClinicalExpensesCurrent
1233000 usd
CY2023Q3 pbyi Accrued Professional Fees Liability Current
AccruedProfessionalFeesLiabilityCurrent
860000 usd
CY2022Q4 pbyi Accrued Professional Fees Liability Current
AccruedProfessionalFeesLiabilityCurrent
1649000 usd
CY2023Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1848000 usd
CY2022Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1731000 usd
CY2023Q3 pbyi Accrued Manufacturing Costs Current
AccruedManufacturingCostsCurrent
664000 usd
CY2022Q4 pbyi Accrued Manufacturing Costs Current
AccruedManufacturingCostsCurrent
553000 usd
CY2023Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
264000 usd
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
215000 usd
CY2023Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
33773000 usd
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
53034000 usd
CY2023Q3 pbyi Accrued Legal Verdict Expense Noncurrent
AccruedLegalVerdictExpenseNoncurrent
7618000 usd
CY2022Q4 pbyi Accrued Legal Verdict Expense Noncurrent
AccruedLegalVerdictExpenseNoncurrent
7354000 usd
CY2023Q3 us-gaap Other Accrued Liabilities Noncurrent
OtherAccruedLiabilitiesNoncurrent
121000 usd
CY2022Q4 us-gaap Other Accrued Liabilities Noncurrent
OtherAccruedLiabilitiesNoncurrent
37000 usd
CY2023Q3 pbyi Accrued Liabilities Noncurrent
AccruedLiabilitiesNoncurrent
7739000 usd
CY2022Q4 pbyi Accrued Liabilities Noncurrent
AccruedLiabilitiesNoncurrent
7391000 usd
CY2023Q3 us-gaap Accrued Liabilities Current And Noncurrent
AccruedLiabilitiesCurrentAndNoncurrent
41512000 usd
CY2022Q4 us-gaap Accrued Liabilities Current And Noncurrent
AccruedLiabilitiesCurrentAndNoncurrent
60425000 usd
CY2023Q3 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
102000000 usd
CY2023Q3 us-gaap Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net
DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
2702000 usd
CY2023Q3 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
76634000 usd
CY2023Q3 us-gaap Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year
LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear
0 usd
CY2023Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
33997000 usd
CY2023Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
45329000 usd
CY2023Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
22674000 usd
CY2023Q3 us-gaap Long Term Debt
LongTermDebt
102000000 usd
CY2023Q3 us-gaap Accumulated Amortization Deferred Finance Costs
AccumulatedAmortizationDeferredFinanceCosts
2708000 usd
CY2022Q4 us-gaap Accumulated Amortization Deferred Finance Costs
AccumulatedAmortizationDeferredFinanceCosts
1717000 usd
CY2023Q3 us-gaap Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net
DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
2702000 usd
CY2022Q4 us-gaap Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net
DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
3693000 usd
CY2023Q3 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
200000 usd
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
600000 usd
CY2023Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2023Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2011Q4 pbyi Ordinary Shares Ownership Percentage
OrdinarySharesOwnershipPercentage
0.20 pure
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2545000 usd
CY2022Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2830000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
7815000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
9198000 usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
3.17
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.72
CY2022Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
799376
CY2022Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
4.25
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
581614
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
3.17
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
649116
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
4.12
CY2023Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
731874
CY2023Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
3.52
us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
1400000 usd
us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
1200000 usd
CY2014Q3 pbyi Milestone Payments Maximum Amount
MilestonePaymentsMaximumAmount
187500000 usd
CY2023Q1 pbyi Percentage Of Unpaid Portion Of Milestone Payments Interest Rate
PercentageOfUnpaidPortionOfMilestonePaymentsInterestRate
0.0625 pure
CY2021Q3 pbyi Milestone Payment
MilestonePayment
1800000 usd

Files In Submission

Name View Source Status
pbyi-20230930_def.xml Edgar Link unprocessable
pbyi-20230930_cal.xml Edgar Link unprocessable
pbyi-20230930_pre.xml Edgar Link unprocessable
0001437749-23-030028-index-headers.html Edgar Link pending
0001437749-23-030028-index.html Edgar Link pending
0001437749-23-030028.txt Edgar Link pending
0001437749-23-030028-xbrl.zip Edgar Link pending
ex_568692.htm Edgar Link pending
ex_568693.htm Edgar Link pending
ex_568694.htm Edgar Link pending
ex_568695.htm Edgar Link pending
ex_568696.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
pbyi-20230930.xsd Edgar Link pending
pbyi20230930_10q.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
pbyi-20230930_lab.xml Edgar Link unprocessable
pbyi20230930_10q_htm.xml Edgar Link completed
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending